Arto Urtti received his Ph.D. in pharmaceutics at the University of Kuopio, Finland, where he later served as associate professor of pharmaceutical technology and professor of biopharmaceutics. Thereafter, he worked at the University of Helsinki as director of the Centre for Drug Research and professor of biopharmaceutics (currently). He is also employed at the University of Eastern Finland (part-time). Dr. Urtti performed postdoctoral research at the Department of Pharmaceutical Chemistry, University of Kansas, and later was a visiting associate professor and professor at the Department of Bio-Pharmaceutical Sciences, University of California, San Francisco. His main research fields are ocular drug delivery, preclinical ADME, and pharmaceutical nanotechnology. He has published ~280 publications, which have been cited >7,300 times, and he received awards such as AAPS Fellowship, the Millennium Distinction Prize, Membership in the Finnish Academy of Science and Letters, the EUFEPS Distinguished Service Award, and EUFEPS Senate Membership. So far, 39 students in his research group have received PhDs. He was the first head of the National Graduate School in Pharmaceutical Research and served on the executive committees of international graduate school networks (GPEN, ULLA). He has been an expert for many funding agencies, for example, EU-FP7, ERC, MRC, Welcome Trust, and French National Research Agency. He was editor-in-chief of the European Journal of Pharmaceutical Sciences (2001–2011) and academic editor of PLoS ONE (2007–2012). He serves as a scientific advisor of several international pharmaceutical companies. His research funding is from the Academy of Finland, European Union, FDA, and the pharmaceutical industry.
The Controlled Release Society is an important cross-disciplinary organization in the field of controlled drug delivery. CRS should represent the field internationally so that European and Asian experts would be more efficiently integrated into CRS. Controlled drug delivery is facing important scientific challenges. Current biological sciences are progressing very fast, and these developments introduce major challenges and opportunities for the science of controlled drug delivery. New emerging fields include cell therapy, immunotherapies, new players of the RNA world. Experts of modern biology should become more visible in CRS. Another challenge is to identify and promote drug delivery technologies that can be translated into clinical practise. Clinical translation of drug delivery technologies has been successful in many fields (e.g., transdermal patches). However, the clinical translation has failed in many other fields of drug delivery (e.g., drug targeting), even though nanomedicine has been widely investigated and promoted. Identification of new technologies and fresh drug delivery applications are needed in the future.